Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Jan;2(1):97-100.
doi: 10.3892/br.2013.201. Epub 2013 Nov 19.

The S protein of hepatitis B virus promotes collagen type I expression in hepatic stellate cells by virtue of hepatocytes

Affiliations

The S protein of hepatitis B virus promotes collagen type I expression in hepatic stellate cells by virtue of hepatocytes

Xudong Liu et al. Biomed Rep. 2014 Jan.

Abstract

This study was conducted in order to investigate whether hepatitis B surface S protein (HBs) was able to directly or indirectly promote the proliferation and expression of collagen type I (Col I) and α-smooth muscle actin (α-SMA) in hepatic stellate cells (HSCs). The LX-2 human cell line and the HepG2 human hepatocellular carcinoma cell line were employed as HSCs and as hepatocytes, respectively. Recombinant HBs was added to the LX-2 cells for 48 h and the cell proliferation was assessed by the MTT assay. Col I and α-SMA were measured in the supernatant by ELISA, following treatment of the LX-2 and/or HepG2 cells with recombinant HBs. Transforming growth factor-β1 (TGF-β1) was also determined by ELISA in the HepG2 cell supernatants. The data demonstrated that high concentrations of recombinant HBs (10-50 ng/ml) inhibited the proliferation of LX-2 cells, whereas low concentrations (0.5-5 ng/ml) did not affect LX-2 cell proliferation. After treating LX-2 cells alone with recombinant HBs for 48 h, there was no significant increase in the Col I and α-SMA levels. However, Col I was increased ~1.7-fold in co-cultured (LX-2 and HepG2) cell supernatants following treatment with HBs for 24 h (HBs vs. control group: 48.51±3.51 vs. 28.23±2.55 ng/ml, respectively). Furthermore, TGF-β1 was significantly increased in the HepG2 cell supernatants following treatment with recombinant HBs. Therefore, we concluded that HBs directly affected the proliferation of HSCs, but promoted the Col I expression in HSCs possibly by virtue of hepatocytes secreting TGF-β1. This may provide a novel explanation of the fibrogenetic mechanism induced by hepatitis B virus-related proteins.

Keywords: LX-2 cell line; S protein; fibrosis; hepatic stellate cells; hepatitis B virus.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Effects of hepatitis B surface S protein (HBs) on LX-2 cell proliferation. The LX-2 cells were incubated with various concentrations of HBs. High concentrations of HBs (10–50 ng/ml) inhibited the proliferation of LX-2 cells, whereas low concentrations (0.5–5 ng/ml) did not affect LX-2 cell proliferation. No significant difference was observed in LX-2 cell survival, although the optical density (OD) value was increased, when HBs concentration reached a plateau of 1–5 ng/ml. *P<0.05. Error bars, ±2.00 SE.
Figure 2
Figure 2
Effect of hepatitis B surface S protein (HBs) on secretion of α-smooth muscle actin (α-SMA) and collagen type I (Col I) in LX-2 cells and the co-culture system of HepG2 and LX-2 cells. To detect the effect of HBs on the expression of Col I and α-SMA in LX-2 cells, the cells (2×103 cells/well) were cultured for 24 h, then incubated with HBs (10 ng/ml) for 48 h. The change in Col I and α-SMA levels was no different between the HBs treatment and the control groups (data not shown): Col I, 28.61±3.25 vs. 26.30±3.69 ng/ml, t=0.47, P=0.648 and α-SMA, 25.08±5.33 vs. 24.48±2.62 ng/ml, t=0.101, P=0.962, respectively. HepG2 (2×103 cells/well) and LX-2 cells (2×103 cells/well) were co-cultured for 24 h, then incubated with HBs (10 ng/ml) for 24 h. Col I was found to be significantly increased following HBs treatment (48.51±3.51 vs. 28.23±2.55 ng/ml, t=4.674, P=0.001), whereas there was no obvious change in α-SMA (data not shown; 30.66±2.69 vs. 23.42±3.86 ng/ml, t=1.538, P=0.155). The HepG2 cells (2×103 cells/well) were cultured alone with HBs for 24 h to eliminate the secretion of Col I and α-SMA. The results demonstrated that Col I was increased in HepG2 cell supernatants (37.63±3.43 vs. 18.49±3.58 ng/ml, t=3.856, P=0.003), although α-SMA was not (20.70±2.38 vs. 18.46±1.48 ng/ml, t=0.799, P=0.443). However, Col I was significantly lower in the supernatant of HepG2 cells stimulated by HBs than in the supernatant of the co-culture system (37.63±3.43 vs. 48.51±3.51 ng/ml, t=3.132, P=0.03), whereas the data did not reveal similar results for α-SMA. Error bars, ±2.00 SE.
Figure 3
Figure 3
Effect of hepatitis B surface S protein (HBs) on the secretion of transforming growth factor-β1 (TGF-β1) in HepG2 cells. To elucidate the mechanism underlying the effect of HepG2 on LX-2 cells, the HepG2 cells (2×103 cells/well) were cultured for 24 h, then incubated with HBs (10 ng/ml) for 24 h. The results demonstrated that the TGF-β1 levels were higher in the HBs treatment group compared to those in the control group (9.80±1.89 vs. 6.49±1.41 ng/ml, t=3.635, P=0.005). *P<0.05. Error bars, ±2.00 SE.

Similar articles

Cited by

References

    1. Ocama P, Opio CK, Lee WM. Hepatitis B virus infection: current status. Am J Med. 2005;118:1413. - PubMed
    1. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat. 2004;11:97–107. - PubMed
    1. Kao JH, Chen DS. Global control of hepatitis B virus infection. Lancet Infect Dis. 2002;2:395–403. - PubMed
    1. Lee WM. Hepatitis B virus infection. N Engl J Med. 1997;337:1733–1745. - PubMed
    1. Ganem D, Prince AM. Hepatitis B virus infection - natural history and clinical consequences. N Engl J Med. 2004;350:1118–1129. - PubMed

LinkOut - more resources